Nuo Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
AURXStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Item 6. | Exhibits. |
|---|
| Exhibit Number | Description |
| 3.1 | Second Amended and Restated Certificate of Incorporation of Nuo Therapeutics, Inc. (previously filed on May 10, 2016 as Exhibit 3.1 to the registrant’s Registration Statement on Form 8-A and incorporated by reference herein). |
| 3.2 | Certificate of Designation of Series A Preferred Stock of Nuo Therapeutics, Inc. (previously filed on May 10, 2016 as Exhibit 3.3 to the registrant’s Current Report on Form 8-K and incorporated by reference herein). |
| 3.3 | Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Nuo Therapeutics, Inc. (previously filed on September 5, 2018 as Exhibit 3.1 to the registrant’s Current Report on Form 8-K and incorporated by reference herein). |
| 3.4 | Amended and Restated By-Laws of Nuo Therapeutics, Inc. (previously filed on May 10, 2016 as Exhibit 3.2 to the registrant’s Registration Statement on Form 8-A and incorporated by reference herein). |
| 4.1 | Form of Interim Warrants (as issued in connection with Loan and Security Agreement dated as of May 29, 2026) (previously filed on June 3, 2026 as Exhibit 4.1 to the registrant's Current Report on Form 8-K and incorporated herein by reference) |
| 4.2 | Form of Second Warrants (as issued in connection with Loan and Security Agreement dated as of January 21, 2026) (previously filed on January 26, 2026 as Exhibit 4.2 to the registrant's Current Report on Form 8-K and incorporated by reference herein) |
| 4.3 | Form of Second Restated Warrants (as issued in connection with Loan and Security Agreement dated as of May 29, 2026) (previously filed on June 3, 2026 as Exhibit 4.3 to the registrant's Current Report on Form 8-K and incorporated herein by reference) |
| 4.4 | Form of Prepayment Warrants (as issued in connection with Loan and Security Agreement dated as of January 21, 2026) (previously filed on January 26, 2026 as Exhibit 4.3 to the registrant's Current Report on Form 8-K and incorporated by reference herein) |
| 4.5 | Form of Prepayment Restated Warrants (as issued in connection with Loan and Security Agreement dated as of May 29, 2026) (previously filed on June 3, 2026 as Exhibit 4.4 to the registrant's Current Report on Form 8-K and incorporated herein by reference) |
| 4.6 | Form of Interest Warrants (as issuable in connection with Loan and Security Agreement dated as of January 21, 2026) (previously filed on January 26, 2026 as Exhibit 4.4 to the registrant's Current Report on Form 8-K and incorporated by reference herein) |
| 10.1 | Amended and Restated Loan and Security Agreement, dated as of May 29, 2026 (previously filed on June 3, 2026 as Exhibit10.1 to the registrant's Current Report on Form 8-K and incorporated herein by reference) |
| 31 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101 | The following materials from Nuo Therapeutics, Inc. Form 10-Q for the quarter ended June 30, 2026, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) Consolidated Balance Sheets at June 30, 2026 and December 31, 2025, (ii) Consolidated Statements of Operations for the three and six month periods ended June 30, 2026 and 2025, (iii) Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three and six month periods ended June 30, 2026 and 2025, (iv) Consolidated Statements of Cash Flows for the six month periods ended June 30, 2026 and 2025 and (v) Notes to the Unaudited Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.